Cancer Immunotherapy and Biomarkers

This study uses single-cell RNA-seq data to analyze cell-cell communication changes in breast cancer patients during anti-PD-1 therapy, identifying key pathways and potential therapeutic targets.

The paper develops a CRISPR screening framework to map kinase-dependent immune evasion mechanisms in glioblastoma by integrating single-cell transcriptomics and deep generative models.

ACB1801 enhances anti-PD-1 therapy efficacy in MSS CRC by reprogramming the TME through metabolic reprogramming and STAT1 signaling activation.

The paper introduces a modular pipeline for neoantigen discovery, verification, and prioritization in cancer research using immunopeptidogenomic data.

This study shows that PD-1 ligand interactions are force-dependent and soluble PD-L1 can block PD-1, suggesting new approaches for cancer immunotherapy.

This study examines neutrophil infiltration patterns in lymph nodes during adoptive T cell therapy in mice, revealing differences between tumor-draining and non-tumor-draining lymph nodes.

This study presents an eco-evolutionary model showing how tumor mutational burden influences immunotherapy success and resistance through trade-offs between oncogenic and immunogenic mutations.

This study shows that reducing tumor glycolysis improves immunotherapy responses by normalizing the tumor microenvironment and enhancing immune cell activity.

This study shows that intratumoral plasma cells are essential for CD8+ T cell activation and response to immune checkpoint blockade therapy in MPNSTs.

This study shows hypoxia blocks C1APP pathway components in lung cancer cells, leading to reduced immunopeptide presentation and immunogenic dormancy via stress granules.

This paper identifies neoantigen peptides and immune subtypes in TNBC using genomic and transcriptomic data, finding potential vaccine targets and biomarkers for immune stratification.

This study shows that combining radiation therapy with BET inhibition enhances anti-tumor immunity in immunologically cold tumors in mice.

This study identifies that radiotherapy-induced antitumor immunity involves ERV reactivation and RNA virus sensing, with SFRT showing stronger immune responses than conventional RT.

This study shows CD40 agonist therapy reduces tumor growth in antigen presentation-deficient tumors by reprogramming monocytes and requiring IFN-gamma and CD8+ T cells for efficacy.

This study shows that activating pattern recognition receptors in tumors enhances stem cell-like memory CD8 T cells, improving antitumor immunity when combined with radiation in lung and bladder cancer models.

This study shows that tissue injury accelerates tumor growth and reduces response to immunotherapy in mice, but biomaterials that enhance wound healing can improve outcomes and ICB response.

The paper introduces AlphaTMB, a composite biomarker combining tumor mutation burden with pathogenicity scores, showing improved survival prediction in immunotherapy response.

This study identifies HOXD13 as a driver of a developmental program in melanoma that promotes angiogenesis and suppresses T-cell infiltration through a gene regulatory axis involving VEGFA, SEMA3A, and CD73.

The paper shows that CMTM6 suppresses FAS expression in mice but not humans, highlighting species differences in CMTM6-FAS interaction.

This study shows that vaccinating against tumor-associated mitochondrial antigens enhances CD8+ T cell recognition of endothelial cells, improving immune response and survival in RCC models.

This paper shows that blocking PVR and Nectin-2 reactivates macrophage anti-tumor functions and reduces cervical tumor growth in pre-clinical models.

The paper identifies CD14+CD4+ T cells in NSCLC tumor microenvironment driven by TNF, linked to poor patient survival.

The paper shows that sustained cell volume expansion in melanoma primes cells to develop drug tolerance while increasing susceptibility to CD8+ T cell killing.

This paper identifies AADAT as a metabolic immune checkpoint in TNBC that promotes immune evasion by regulating malate and CoQ10, and shows that malate supplementation can reverse immunotherapy resistance.

This study shows that macrophages target PVR/CD155 on colorectal cancer cells via REVERBα, suggesting a new therapeutic strategy for MSS+ CRC.

This study uses multi-omics profiling to show that house dust mite exposure accelerates lung tumor growth through immune-mediated mechanisms by altering the tumor microenvironment.

Combining TCE therapy with IL-2 enhances TCE efficacy in aggressive small-cell lung cancer and melanoma models with low target antigen density through T cell clonal replacement and CD8+ effector T cell differentiation.

This study investigates how AMPK and BET proteins regulate immune checkpoint molecules in TNBC patients with T2D, suggesting personalized ICB treatment strategies.

This paper shows that FAK inhibition remodels the metastatic ECM, enhancing CD8+ T cell infiltration and immunosurveillance in breast cancer.